TMC (Topotecan, Cyclophosphamide and Melphalan) for Multiple Myeloma

Completed · Phase 2

Conditions studied: Myeloma

In brief

To determine the efficacy of high-dose topotecan, cyclophosphamide and melphalan in patients with Multiple Myeloma.

Key facts

Study ID

NCT01039025

Run by

M.D. Anderson Cancer Center

People needed

60

Starts

2002-02-18

Expected to finish

2006-05-19

Last updated by the study team

2018-11-07

Who can join

Age: any, up to 70. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients with intermediate or high tumor mass multiple myeloma with responsive or primary refractory disease; and patients with responsive or refractory relapse.
• Physiological age </= 70.
• Zubrod performance status < 3.
• Life expectancy greater than 12 weeks.
• Left ventricular ejection fraction >/= 50%.
• No uncontrolled arrythmias or symptomatic cardiac disease.
• FEV1, FVC and DLCO >/= 50%.
• No symptomatic pulmonary disease.
• Serum creatinine < 1.5 mg/dL.
• Serum bilirubin < 2x upper limit of normal.
• No evidence of chronic or active hepatitis or cirrhosis.
• Patient is not pregnant.
• Patients or guardian able to sign informed consent.
• No active CNS disease.
• Platelet count > 100K.

You may not qualify if…

• N/A

Where it is running

• U.T. M.D. Anderson Cancer Center — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.